Relationship between Parathyroid Hormone Level and Early Remodeling Heart Failure after Acute Myocardial Infarction
Background: Previous studies have indicated that parathyroid hormone (PTH) has been linked to post-myocardial infarction (MI) development. The aim of this cross-sectional study was to evaluate the relationship between PTH level and heart failure due to post-infarction remodeling during the first 72 hours of hospitalization.
Method: 70 patients with a diagnosis of acute MI (age ≥18 years, 22 females and 48 males) were enrolled. Patients were admitted to the Imam Raza Educational, Research and Treatment Center, Mashhad University of Medical Sciences, Iran between July 2014 to September 2015. First blood samples were taken from all patients during the first 24 hours of admission to the hospital. The second samples were taken after 72 hours.
Results: Based on our findings, during the first 72 hours, the PTH level significantly increased in patients with Post-Myocardial Infarction Heart Failure. We also measured vitamin D level. Eighty- six percent of the subjects of the study had an inappropriate vitamin D level at the time of admission. Mean levels of vitamin D and PTH increased compared with the baselines (95% CI, 0.15 to 10.03, P = 0.044), (95% CI, 6.5 to 24.8, P = 0.001) respectively.
Conclusion: During the first 72 hours, the PTH level significantly increased in patients with heart failure due to post- infarction remodeling. Among these patients, PTH excess was associated with Post-Myocardial Infarction Heart Failure. Acute elevations of serum PTH levels increased early remodeling heart failure after MI. Serum vitamin D status was independent of high serum PTH level.
2. Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. Cell and tissue research. 2016;365(3):563-81.
3. Bhat P, Tang WW. Biomarkers to Assess and Guide the Management of Heart Failure. Biomarkers in Cardiovascular Disease: Elsevier; 2019. p. 97-108.
4. Ho HCH, Maddaloni E, Buzzetti R. Risk Factors and Predicitve Biomarkers of Early Cardiovascular Disease in Obese Youth. Diabetes/Metabolism Research and Reviews. 2019:e3134.
5. Piek A, Du W, de Boer RA, Silljé HH. Novel heart failure biomarkers: why do we fail to exploit their potential? Critical reviews in clinical laboratory sciences. 2018;55(4):246-63.
6. Ruiz PR, Huertas LJ, Sancirilo MC, Díaz JM, Ruipérez GC, de Guadiana Romualdo LG, et al. Parathyroid hormone, calcidiol, calcitriol and adverse events in the acute coronary syndrome. Medicina Intensiva (English Edition). 2018;42(2):73-81.
7. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Progress in biophysics and molecular biology. 2006;92(1):39-48.
8. Bailey L, Smyl D, Bossuyt S, Bossuyt J. Quantifying Nuclear Remodeling in Heart Failure. Biophysical Journal. 2018;114(3):499a.
9. Yagi S, Aihara K-i, Kondo T, Endo I, Hotchi J, Ise T, et al. High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients. Endocrine journal. 2014;61(7):727-33.
10. Wu GY, Wu T, Xu BD, Shi YC, Cheng ZY, Zhang X, et al. Effect of parathyroid hormone on cardiac function in rats with cardiomyopathy. Experimental and therapeutic medicine. 2018;16(4):2859-66.
11. Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JEB. Parathyroid hormone and vitamin D—markers for cardiovascular and all cause mortality in heart failure. European journal of heart failure. 2011;13(6):626-32.
12. Kaźmierski Ł, Bajek A, Dębski R, Bodnar M, Roszkowski K. Does the conditioned medium trigger the adipose-derived mesenchymal stem cells differentiation into Chondrocytes? Medical Research Journal. 2018;3(3):148-52.
13. Lisowska A, Musial W. Heart failure in patients with chronic kidney disease. Rocz Akad Med Bialymst. 2004;49:162-5.
14. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. Journal of the American Society of Nephrology. 1994;4(10):1814-9.
15. Huber BC, Fischer R, Brunner S, Groebner M, Rischpler C, Segeth A, et al. Comparison of parathyroid hormone and G-CSF treatment after myocardial infarction on perfusion and stem cell homing. American Journal of Physiology-Heart and Circulatory Physiology. 2
16. Gupta S. Disparities in multiple risk factors for cardiovascular diseases-Delaware, 2011. Delaware medical journal. 2014;86(3):77-84.
17. Zarei B, Mousavi M, Mehdizadeh S, MehradMajd H, Zarif M, Arghavanian ZE, et al. Early effects of atorvastatin on Vitamin D and parathyroid hormone serum levels following acute myocardial infarction. J Res Pharm Pract 2019; Jan-Mar;8(1):7-12. doi: 10.4103/jrpp.JRPP_18_55.
18. Bansal N, Zelnick L, Robinson‐Cohen C, Hoofnagle AN, Ix JH, Lima JA, et al. Serum parathyroid hormone and 25‐hydroxyvitamin D concentrations and risk of incident heart failure: the multi‐ethnic study of atherosclerosis. Journal of the American Heart Association. 2014;3(6):e001278.
19. Fujii H. Association between Parathyroid Hormone and Cardiovascular Disease. Therapeutic Apheresis and Dialysis. 2018;22(3):236-41. Totally incomprehensible. Please write it again.